Wave life sciences reports first quarter 2022 financial results and provides business update

Delivered first clinical data demonstrating target engagement and translation of pn chemistry's impact in clinic; adapting ongoing phase 1b/2a focus-c9 clinical trial to optimize dose level and frequency, with additional single and multidose data expected throughout 2022
WVE Ratings Summary
WVE Quant Ranking